| # | Title | Journal | Year | Citations |
|---|
| 1 | Statin Adverse Effects | American Journal of Cardiovascular Drugs | 2008 | 564 |
| 2 | Interactions Between Grapefruit Juice and Cardiovascular Drugs | American Journal of Cardiovascular Drugs | 2004 | 188 |
| 3 | Endogenous and Exogenous Cardiac Glycosides and their Mechanisms of Action | American Journal of Cardiovascular Drugs | 2007 | 185 |
| 4 | Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor | American Journal of Cardiovascular Drugs | 2013 | 179 |
| 5 | The Cardioprotection of the Insulin-Mediated PI3K/Akt/mTOR Signaling Pathway | American Journal of Cardiovascular Drugs | 2014 | 161 |
| 6 | Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus | American Journal of Cardiovascular Drugs | 2011 | 154 |
| 7 | Cancer of the Heart | American Journal of Cardiovascular Drugs | 2003 | 149 |
| 8 | Current Overview on Hypercoagulability in COVID-19 | American Journal of Cardiovascular Drugs | 2020 | 145 |
| 9 | Beyond Low-Density Lipoprotein | American Journal of Cardiovascular Drugs | 2005 | 142 |
| 10 | Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects | American Journal of Cardiovascular Drugs | 2014 | 133 |
| 11 | Bacterial Pericarditis | American Journal of Cardiovascular Drugs | 2005 | 131 |
| 12 | Management of Statin Intolerance in 2018: Still More Questions Than Answers | American Journal of Cardiovascular Drugs | 2018 | 130 |
| 13 | The Role of Paraoxonase 1 Activity in Cardiovascular Disease | American Journal of Cardiovascular Drugs | 2004 | 123 |
| 14 | Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies | American Journal of Cardiovascular Drugs | 2013 | 119 |
| 15 | The Role of the Platelet in the Pathogenesis of Atherothrombosis | American Journal of Cardiovascular Drugs | 2005 | 115 |
| 16 | Cocaine Cardiotoxicity | American Journal of Cardiovascular Drugs | 2009 | 111 |
| 17 | Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy | American Journal of Cardiovascular Drugs | 2005 | 108 |
| 18 | Calcium Intake and Risk of Cardiovascular Disease | American Journal of Cardiovascular Drugs | 2012 | 107 |
| 19 | Testosterone and Atherosclerosis in Aging Men | American Journal of Cardiovascular Drugs | 2005 | 106 |
| 20 | Cilostazol | American Journal of Cardiovascular Drugs | 2003 | 105 |
| 21 | COVID-19 Pandemic: Cardiovascular Complications and Future Implications | American Journal of Cardiovascular Drugs | 2020 | 98 |
| 22 | Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-inflammatory Drugs in the Prevention of Atherothrombosis | American Journal of Cardiovascular Drugs | 2015 | 95 |
| 23 | Dyslipidemia in Visceral Obesity | American Journal of Cardiovascular Drugs | 2004 | 94 |
| 24 | Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease | American Journal of Cardiovascular Drugs | 2018 | 92 |
| 25 | Coadministration of Dabigatran Etexilate and Atorvastatin | American Journal of Cardiovascular Drugs | 2009 | 89 |
| 26 | Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects | American Journal of Cardiovascular Drugs | 2019 | 88 |
| 27 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa | American Journal of Cardiovascular Drugs | 2016 | 87 |
| 28 | Compliance with Antihypertensive Therapy in the Elderly | American Journal of Cardiovascular Drugs | 2008 | 85 |
| 29 | Drug Treatment of Acute Ischemic Stroke | American Journal of Cardiovascular Drugs | 2013 | 85 |
| 30 | Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial | American Journal of Cardiovascular Drugs | 2016 | 82 |
| 31 | Mechanisms, Manifestations, and Management of Digoxin Toxicity in the Modern Era | American Journal of Cardiovascular Drugs | 2006 | 81 |
| 32 | Clinical Pharmacology and Cardiovascular Safety of Naproxen | American Journal of Cardiovascular Drugs | 2017 | 81 |
| 33 | Hypercoagulability in Renal Transplant Recipients | American Journal of Cardiovascular Drugs | 2004 | 80 |
| 34 | The Real Role of β-Blockers in Daily Cardiovascular Therapy | American Journal of Cardiovascular Drugs | 2017 | 79 |
| 35 | Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia | American Journal of Cardiovascular Drugs | 2010 | 78 |
| 36 | Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease | American Journal of Cardiovascular Drugs | 2014 | 76 |
| 37 | Septic Thrombophlebitis | American Journal of Cardiovascular Drugs | 2006 | 75 |
| 38 | Fully Biodegradable Coronary Stents | American Journal of Cardiovascular Drugs | 2008 | 75 |
| 39 | Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients) | American Journal of Cardiovascular Drugs | 2014 | 74 |
| 40 | Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy | American Journal of Cardiovascular Drugs | 2011 | 73 |
| 41 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? | American Journal of Cardiovascular Drugs | 2016 | 72 |
| 42 | Cardiovascular Risk-Benefit Profile of Sibutramine | American Journal of Cardiovascular Drugs | 2010 | 71 |
| 43 | Fenofibrate | American Journal of Cardiovascular Drugs | 2011 | 71 |
| 44 | New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations | American Journal of Cardiovascular Drugs | 2014 | 71 |
| 45 | Therapeutic Potential of Rho-Kinase Inhibitors in Cardiovascular Diseases | American Journal of Cardiovascular Drugs | 2005 | 70 |
| 46 | Effect of Antihypertensive Agents on Arterial Stiffness as Evaluated by Pulse Wave Velocity | American Journal of Cardiovascular Drugs | 2001 | 69 |
| 47 | Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study | American Journal of Cardiovascular Drugs | 2018 | 69 |
| 48 | Adenosine and the Cardiovascular System | American Journal of Cardiovascular Drugs | 2019 | 67 |
| 49 | Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options | American Journal of Cardiovascular Drugs | 2009 | 67 |
| 50 | Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity | American Journal of Cardiovascular Drugs | 2016 | 66 |
